Clinical comparison · GLP-1 & weight management · Updated 2026-07-02
Tirzepatide is an injectable dual GIP/GLP-1 receptor agonist; metformin is an oral biguanide. This table reproduces FDA-labeled and trial-reported facts verbatim, per cell. They are different classes studied for different endpoints, so the outcomes are not directly comparable. The page reports facts and does not rank the two.
Every value below is reproduced verbatim from an FDA prescribing-information document or a published clinical trial, and each cell links to its source. This page does not rank the two options, does not declare one safer or more effective, and is not medical advice.
| Dimension | Tirzepatide | Metformin |
|---|---|---|
| Drug class | Dual GIP and GLP-1 receptor agonist[1] | Biguanide (insulin sensitizer)[2] |
| Route | Once-weekly subcutaneous injection[1] | Oral tablet (immediate- or extended-release)[2] |
| Most common GI adverse event | Nausea 12-18%; diarrhea 12-17%[1] | Diarrhea 53.2% (monotherapy)[2] |
| Reported outcome | -20.9% mean body-weight change at week 72 vs -3.1% placebo (SURMOUNT-1, 15 mg)[3] | Improves ovulation and pregnancy rates vs placebo in PCOS (Cochrane)[4] |
| Serious labeled risk | Boxed warning: thyroid C-cell tumors (MTC/MEN 2 contraindication)[1] | Lactic acidosis (rare); risk rises with renal impairment[2] |
| Pregnancy | Not recommended; discontinue >=2 months before a planned pregnancy[1] | Sometimes continued under specialist care (historical category B)[2] |
Different endpoints, not comparable
SURMOUNT-1 measured percentage body-weight change for tirzepatide; the Cochrane metformin review measured ovulation and pregnancy rates in PCOS. The endpoints, designs, and populations differ, so these are not a head-to-head. SURMOUNT-1 (NEJM 2022)
No. Tirzepatide is a once-weekly subcutaneous injection, while metformin is an oral tablet (FDA labels).
SURMOUNT-1 reported a mean body-weight change of -20.9% at week 72 on the 15 mg dose versus -3.1% with placebo.
Editorial reviews from ClearHormones of telehealth providers in this category. These are not treatment recommendations, and prescribing decisions rest with a licensed clinician.